224 related articles for article (PubMed ID: 27123695)
1. A double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [
Guerini E; Schadt S; Greig G; Haas R; Husser C; Zell M; Funk C; Hartung T; Gloge A; Mallalieu NL
Xenobiotica; 2017 Feb; 47(2):144-153. PubMed ID: 27123695
[TBL] [Abstract][Full Text] [Related]
2. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans.
Schwab D; Portron A; Backholer Z; Lausecker B; Kawashima K
Clin Pharmacokinet; 2013 Jun; 52(6):463-73. PubMed ID: 23494983
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression.
Lindemann L; Porter RH; Scharf SH; Kuennecke B; Bruns A; von Kienlin M; Harrison AC; Paehler A; Funk C; Gloge A; Schneider M; Parrott NJ; Polonchuk L; Niederhauser U; Morairty SR; Kilduff TS; Vieira E; Kolczewski S; Wichmann J; Hartung T; Honer M; Borroni E; Moreau JL; Prinssen E; Spooren W; Wettstein JG; Jaeschke G
J Pharmacol Exp Ther; 2015 Apr; 353(1):213-33. PubMed ID: 25665805
[TBL] [Abstract][Full Text] [Related]
4. A Dual-Administration Microtracer Technique to Characterize the Absorption, Distribution, Metabolism, and Excretion of [
Helmer E; Nicolas JM; Long J; Roffel AF; Jones E; Chanteux H; Diaz N; Garratt H; Bosje T
J Clin Pharmacol; 2017 Dec; 57(12):1582-1590. PubMed ID: 28650526
[TBL] [Abstract][Full Text] [Related]
5. Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.
Zollinger M; Lozac'h F; Hurh E; Emotte C; Bauly H; Swart P
Cancer Chemother Pharmacol; 2014 Jul; 74(1):63-75. PubMed ID: 24817600
[TBL] [Abstract][Full Text] [Related]
6. Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
Reif S; Schultze-Mosgau MH; Engelen A; Piel I; Denner K; Roffel A; Tiessen R; Klein S; Francke K; Rottmann A
Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):71-85. PubMed ID: 38044419
[TBL] [Abstract][Full Text] [Related]
7. Oral bioavailability and disposition of [14C]omapatrilat in healthy subjects.
Malhotra BK; Iyer RA; Soucek KM; Behr D; Liao WC; Mitroka JG; Kaul S; Cohen MB; Knupp CA
J Clin Pharmacol; 2001 Aug; 41(8):833-41. PubMed ID: 11504270
[TBL] [Abstract][Full Text] [Related]
8. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and metabolism of [
Mancel V; Mathy FX; Boulanger P; English S; Croft M; Kenney C; Knott T; Stockis A; Bani M
Xenobiotica; 2017 Aug; 47(8):705-718. PubMed ID: 27489076
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects.
Nave R; Bethke TD; van Marle SP; Zech K
Clin Pharmacokinet; 2004; 43(7):479-86. PubMed ID: 15139796
[TBL] [Abstract][Full Text] [Related]
11. The disposition and pharmacokinetics of alpidem, a new anxiolytic, in the rat.
Garrigou-Gadenne D; Durand A; Thenot JP; Morselli PL
Drug Metab Dispos; 1991; 19(3):574-9. PubMed ID: 1680622
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, absorption, metabolism, and excretion of [
Prakash C; Fan B; Altaf S; Agresta S; Liu H; Yang H
Cancer Chemother Pharmacol; 2019 May; 83(5):837-848. PubMed ID: 30758648
[TBL] [Abstract][Full Text] [Related]
13. Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants.
Devineni D; Murphy J; Wang SS; Stieltjes H; Rothenberg P; Scheers E; Mamidi RN
Clin Pharmacol Drug Dev; 2015 Jul; 4(4):295-304. PubMed ID: 27136910
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans.
Ericsson H; Hamrén B; Bergstrand S; Elebring M; Fryklund L; Heijer M; Ohman KP
Drug Metab Dispos; 2004 Sep; 32(9):923-9. PubMed ID: 15319332
[TBL] [Abstract][Full Text] [Related]
15. Estimating mass balance for inhaled drugs in humans: an example with a VLA-4 antagonist, IVL745.
Rohatagi S; Shah B; Zhang J; Zeng Z; Kirkesseli S; Jensen BK
J Clin Pharmacol; 2004 Apr; 44(4):348-58. PubMed ID: 15051741
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability.
Lappin G; Shishikura Y; Jochemsen R; Weaver RJ; Gesson C; Houston B; Oosterhuis B; Bjerrum OJ; Rowland M; Garner C
Eur J Pharm Sci; 2010 May; 40(2):125-31. PubMed ID: 20307657
[TBL] [Abstract][Full Text] [Related]
17. Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects.
Gerisch M; Hafner FT; Lang D; Radtke M; Diefenbach K; Cleton A; Lettieri J
Cancer Chemother Pharmacol; 2018 Jan; 81(1):195-206. PubMed ID: 29188322
[TBL] [Abstract][Full Text] [Related]
18. Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation-positive solid tumors.
Denton CL; Minthorn E; Carson SW; Young GC; Richards-Peterson LE; Botbyl J; Han C; Morrison RA; Blackman SC; Ouellet D
J Clin Pharmacol; 2013 Sep; 53(9):955-61. PubMed ID: 23846776
[TBL] [Abstract][Full Text] [Related]
19. In vivo bioavailability, absorption, excretion, and pharmacokinetics of [14C]procyanidin B2 in male rats.
Stoupi S; Williamson G; Viton F; Barron D; King LJ; Brown JE; Clifford MN
Drug Metab Dispos; 2010 Feb; 38(2):287-91. PubMed ID: 19910517
[TBL] [Abstract][Full Text] [Related]
20. The Absolute Bioavailability and Absorption, Metabolism, and Excretion of Ipatasertib, a Potent and Highly Selective Protein Kinase B (Akt) Inhibitor.
Takahashi RH; Malhi V; Liederer BM; Cho S; Deng Y; Dean B; Nugteren J; Yost E; Al-Sayah MA; Sane R; Kshirsagar S; Ma S; Musib L
Drug Metab Dispos; 2023 Oct; 51(10):1332-1341. PubMed ID: 37524543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
